News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Menzel Garry E
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 07/10/2023 |
4
| Menzel Garry E (Director) has filed a Form 4 on Adaptimmune Therapeutics PLC|
Txns:
| Sold 47,702 shares
@ $0.9108, valued at
$43.4k
|
|
| 07/05/2023 |
4
| Menzel Garry E (Director) has filed a Form 4 on Adaptimmune Therapeutics PLC|
Txns:
| Granted 736,548 options to buy
@ $0
Granted 1,251,966 options to buy
@ $0
Granted 359,700 options to buy
@ $0
Granted 3,568,026 options to buy
@ $0
Granted 57,846 options to buy
@ $0
Granted 2,715,816 options to buy
@ $0
Granted 2,158,776 options to buy
@ $0 |
|
| 07/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/15/2023 |
4
| Menzel Garry E (Director) has filed a Form 4 on Stoke Therapeutics, Inc.|
Txns:
| Granted 19,441 options to buy
@ $12.46, valued at
$242.2k
|
|
| 06/01/2023 |
4
| Menzel Garry E (Director) has filed a Form 4 on Adaptimmune Therapeutics PLC|
Txns:
| Granted 200,646 shares
@ $0
Granted 200,647 shares
@ $0
Granted 209,931 shares
@ $0 |
|
| 06/01/2023 |
3
| Menzel Garry E (Director) has filed a Form 3 on Adaptimmune Therapeutics PLC |
| 06/01/2023 |
4
| Menzel Garry E (President and CEO) has filed a Form 4 on TCR2 THERAPEUTICS INC.|
Txns:
| Disposed/sold 132,729 shares
@ $0
Disposed/sold 132,730 shares
@ $0
Disposed/sold 138,871 shares
@ $0
Disposed/sold 138,031 options to buy
@ $0.74, valued at
$102.1k
Disposed/sold 433,037 options to buy
@ $5.88, valued at
$2.5M
Disposed/sold 305,800 options to buy
@ $5.21, valued at
$1.6M
Disposed/sold 238,008 options to buy
@ $0.97, valued at
$230.9k
Disposed/sold 3,241 restricted stock units
@ $0
Disposed/sold 15,120 restricted stock units
@ $0
Disposed/sold 23,165 restricted stock units
@ $0
Disposed/sold 39,681 restricted stock units
@ $0 |
|
| 05/17/2023 |
4
| Menzel Garry E (Director) has filed a Form 4 on Black Diamond Therapeutics, Inc.|
Txns:
| Granted 16,500 options to buy
@ $1.82, valued at
$30k
|
|
| 12/19/2022 |
4
| Menzel Garry E (President and CEO) has filed a Form 4 on TCR2 THERAPEUTICS INC.|
Txns:
| Granted 238,008 options to buy
@ $0.97, valued at
$230.9k
Granted 39,681 options to buy
@ $0 |
|
| 12/13/2022 |
4
| Menzel Garry E (President and CEO) has filed a Form 4 on TCR2 THERAPEUTICS INC.|
Txns:
| Sold 10,325 shares
@ $1.131, valued at
$11.7k
Sold 10,613 shares
@ $1.1, valued at
$11.7k
Sold 11,000 shares
@ $1.062, valued at
$11.7k
|
|
| 12/09/2022 |
4
| Menzel Garry E (President and CEO) has filed a Form 4 on TCR2 THERAPEUTICS INC.|
Txns:
| Sold 9,111 shares
@ $1.282, valued at
$11.7k
Sold 9,314 shares
@ $1.254, valued at
$11.7k
|
|
| 12/07/2022 |
4
| Menzel Garry E (President and CEO) has filed a Form 4 on TCR2 THERAPEUTICS INC.|
Txns:
| Sold 8,530 shares
@ $1.372, valued at
$11.7k
Sold 14,886 shares
@ $1.349, valued at
$20.1k
|
|
| 12/05/2022 |
4
| Menzel Garry E (President & CEO) has filed a Form 4 on TCR2 THERAPEUTICS INC.|
Txns:
| Sold 8,408 shares
@ $1.39, valued at
$11.7k
Exercised 158,795 restricted stock units
@ $0
Exercised 40,881 restricted stock units
@ $0
Exercised 21,382 restricted stock units
@ $0 |
|
| 11/18/2022 |
4
| Menzel Garry E (President and CEO) has filed a Form 4 on TCR2 THERAPEUTICS INC.|
Txns:
| Disposed/sold 6,240 options to buy
@ $16.11, valued at
$100.5k
Granted 2,080 options to buy
@ $0
Disposed/sold 479,866 options to buy
@ $16.11, valued at
$7.7M
Granted 159,956 options to buy
@ $0
Disposed/sold 3,500 options to buy
@ $16.1, valued at
$56.4k
Granted 1,167 options to buy
@ $0
Disposed/sold 164,500 options to buy
@ $16.1, valued at
$2.6M
Granted 54,834 options to buy
@ $0
Disposed/sold 4,512 options to buy
@ $31.83, valued at
$143.6k
Granted 821 options to buy
@ $0
Disposed/sold 240,488 options to buy
@ $31.83, valued at
$7.7M
|
|
| 08/26/2022 |
4
| Menzel Garry E (President & CEO) has filed a Form 4 on TCR2 THERAPEUTICS INC.|
Txns:
| Gifted 84,527 shares
@ $0
Gifted 48,202 shares
@ $0
Gifted 48,202 shares
@ $0
Gifted 132,730 shares
@ $0
Gifted 132,730 shares
@ $0 |
|
| 06/13/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/08/2022 |
4
| Menzel Garry E (Director) has filed a Form 4 on Stoke Therapeutics, Inc.|
Txns:
| Granted 21,000 options to buy
@ $12.96, valued at
$272.2k
|
|
| 03/18/2022 |
4
| Menzel Garry E (President & CEO) has filed a Form 4 on TCR2 THERAPEUTICS INC.|
Txns:
| Granted 1,425 shares
@ $2.3, valued at
$3.3k
|
|
| 12/10/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/25/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/22/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/23/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/08/2021 |
4
| Menzel Garry E (President and CEO) has filed a Form 4 on TCR2 THERAPEUTICS INC.|
Txns:
| Granted 1,132 shares
@ $10.098, valued at
$11.4k
Granted 686 shares
@ $16.1245, valued at
$11.1k
|
|
| 01/27/2021 |
4
| Menzel Garry E (Director) has filed a Form 4 on Stoke Therapeutics, Inc.|
Txns:
| Granted 29,555 options to buy
@ $28.57, valued at
$844.4k
|
|
| 01/27/2021 |
3
| Menzel Garry E (Director) has filed a Form 3 on Stoke Therapeutics, Inc. |
| 12/11/2020 |
4
| Menzel Garry E (President and CEO) has filed a Form 4 on TCR2 THERAPEUTICS INC.|
Txns:
| Granted 245,000 options to buy
@ $31.38, valued at
$7.7M
|
|
| 03/27/2020 |
4
| Menzel Garry E (President & CEO) has filed a Form 4 on TCR2 THERAPEUTICS INC.|
Txns:
| Granted 980 shares
@ $12.75, valued at
$12.5k
Granted 1,287 shares
@ $10.1, valued at
$13k
|
|
| 02/05/2020 |
4
| Menzel Garry E (Director) has filed a Form 4 on Black Diamond Therapeutics, Inc.|
Txns:
| Converted 51,825 shares
@ $0
Converted 156,297 preferred shares
@ $0 |
|
| 01/29/2020 |
3
| Menzel Garry E (Director) has filed a Form 3 on Black Diamond Therapeutics, Inc. |
| 12/20/2019 |
4
| Menzel Garry E (President and CEO) has filed a Form 4 on TCR2 THERAPEUTICS INC.|
Txns:
| Granted 168,000 options to buy
@ $16.1, valued at
$2.7M
|
|
| 04/12/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/13/2019 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 09/11/2013 |
3
| Menzel Garry E (Senior Vice President, Finance) has filed a Form 3 on DAVITA HEALTHCARE PARTNERS INC. |
| 09/11/2013 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
|
|